Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

Inclusion Criteria:

- Participation in CZP trial C87014 or C87011

- If female and of childbearing potential, she agrees to participate in this study by
providing written informed consent, has been using adequate contraception since her
last menses, will use adequate contraception during the study and for 12 weeks after
the last dose of study drug (or longer if required by local regulations), is not
lactating, and has had a negative urine pregnancy test on the day of receiving the
first dose of study drug

- Must have provided written informed consent before undergoing any study procedures

Exclusion Criteria:

- History (Hx) of chronic infection, serious or life-threatening infection - (including
Herpes Zoster) within 6 months prior, or any current symptom indicating infection

- Current or recent Hx of severe, progressive and/or uncontrolled renal, hepatic,
hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or
cerebral disease

- Any finding indicative of Tuberculosis at end of previous study

- Known HIV infection

- Persistently abnormal AST (Aspartate Aminotransferase) or ALT (Alanine
Aminotransferase) results (> 2 times upper limit of normal)

- Hemoglobin (Hgb) levels < 9 g/dL or Hematocrit < 30 %

- Total White Blood Cell (WBC) count of < 3.0 x 100/L (< 3000/mm^3)

- Platelet count < 100 x 100 L (100,000/mm^3)

- Serum creatinine > 1.5 times upper limit of normal based on patient age and sex

- Receipt of any biological therapies for RA in 6 months prior to study entry or any
prior treatment (tx) with Tumor Necrosis Factor (TNF) blocking agent (excluding
CDP870)

- Receipt of any vaccination (live, attenuated or killed) in 8 weeks prior to Baseline

- Any other condition which the Principal Investigator judges would make patient
unsuitable for study participation